MX2009009779A - Mutaciones de k-ras y b-raf y terapia con anticuerpos anti-egfr. - Google Patents

Mutaciones de k-ras y b-raf y terapia con anticuerpos anti-egfr.

Info

Publication number
MX2009009779A
MX2009009779A MX2009009779A MX2009009779A MX2009009779A MX 2009009779 A MX2009009779 A MX 2009009779A MX 2009009779 A MX2009009779 A MX 2009009779A MX 2009009779 A MX2009009779 A MX 2009009779A MX 2009009779 A MX2009009779 A MX 2009009779A
Authority
MX
Mexico
Prior art keywords
ras
mutations
methods
raf
present application
Prior art date
Application number
MX2009009779A
Other languages
English (en)
Inventor
Salvatore Siena
Alberto Bardelli
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39666021&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2009009779(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of MX2009009779A publication Critical patent/MX2009009779A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hospice & Palliative Care (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere a mutaciones de K-ras, a polinucleótidos que codifican polipéptidos de K-ras mutantes, y a métodos para identificar mutaciones de K-ras. La presente invención también se refiere a mutaciones de B-raf, a polinucleótidos que codifican polipéptidos de B-raf mutantes, a vectores que contienen esos polinucleótidos, y a métodos para identificar mutaciones de B-raf. La presente solicitud también se refiere a métodos para diagnosticar cáncer; y métodos y kits para pronosticar la utilidad de los agentes de unión específica anti-EGFr en el tratamiento de tumores.
MX2009009779A 2007-03-13 2008-03-11 Mutaciones de k-ras y b-raf y terapia con anticuerpos anti-egfr. MX2009009779A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US90697607P 2007-03-13 2007-03-13
PCT/US2008/003327 WO2008112274A2 (en) 2007-03-13 2008-03-11 K-ras and b-raf mutations and anti-egfr antibody therapy

Publications (1)

Publication Number Publication Date
MX2009009779A true MX2009009779A (es) 2009-09-23

Family

ID=39666021

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009009779A MX2009009779A (es) 2007-03-13 2008-03-11 Mutaciones de k-ras y b-raf y terapia con anticuerpos anti-egfr.

Country Status (20)

Country Link
US (2) US20090075267A1 (es)
EP (2) EP2118322A2 (es)
JP (3) JP2010521154A (es)
AR (1) AR065686A1 (es)
AU (1) AU2008226808B2 (es)
CA (1) CA2680330A1 (es)
CL (1) CL2008000716A1 (es)
CY (1) CY1114159T1 (es)
DK (1) DK2412828T3 (es)
ES (1) ES2426814T3 (es)
HK (1) HK1167005A1 (es)
HR (1) HRP20130764T1 (es)
MX (1) MX2009009779A (es)
PE (1) PE20090690A1 (es)
PL (1) PL2412828T3 (es)
PT (1) PT2412828E (es)
RS (1) RS52932B (es)
SI (1) SI2412828T1 (es)
TW (1) TW200904828A (es)
WO (1) WO2008112274A2 (es)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2370054T3 (es) * 2005-08-24 2011-12-12 Bristol-Myers Squibb Company Biomarcadores y procedimientos para determinar la sensibilidad a moduladores del receptor del factor de crecimiento epidérmico.
ITBO20050646A1 (it) 2005-10-26 2007-04-27 Silicon Biosystem S R L Metodo ed apparato per la caratterizzazione ed il conteggio di particelle
US8768629B2 (en) * 2009-02-11 2014-07-01 Caris Mpi, Inc. Molecular profiling of tumors
RU2008146868A (ru) 2006-05-18 2010-06-27 Кэрис МПИ, Инк.445 Норт Фифс Стрит, 3-ий Флор, Феникс, Аризона 85004, США (US) Система и способ определения персонализированого медицинского вмешательства при болезненном состоянии
EP2118322A2 (en) * 2007-03-13 2009-11-18 Amgen Inc. K-ras and b-raf mutations and anti-egfr antibody therapy
CL2008000717A1 (es) 2007-03-13 2008-09-22 Amgen Inc Metodo para pronosticar si un paciente sera no respondedor al tratamiento con un agente de union especifica a un polipeptido de egfr que comprende determinar la presencia o ausencia de una mutacion de k-ras en un tumor del paciente.
ITTO20070771A1 (it) 2007-10-29 2009-04-30 Silicon Biosystems Spa Metodo e apparato per la identificazione e manipolazione di particelle
EP3216874A1 (en) 2008-09-05 2017-09-13 TOMA Biosciences, Inc. Methods for stratifying and annotating cancer drug treatment options
IT1391619B1 (it) 2008-11-04 2012-01-11 Silicon Biosystems Spa Metodo per l'individuazione, selezione e analisi di cellule tumorali
US10895575B2 (en) 2008-11-04 2021-01-19 Menarini Silicon Biosystems S.P.A. Method for identification, selection and analysis of tumour cells
CN102301002A (zh) 2008-11-12 2011-12-28 卡里斯生命科学卢森堡控股有限责任公司 使用外来体来确定表现型的方法和***
PT3301446T (pt) * 2009-02-11 2020-07-14 Caris Mpi Inc Perfilagem molecular de tumores
CN101487051B (zh) * 2009-02-24 2011-07-20 广州益善生物技术有限公司 Braf基因突变的检测探针、液相芯片及其检测方法
CN102427883B (zh) 2009-03-17 2014-08-20 硅生物***股份公司 用于细胞隔离的微流体装置
SG178866A1 (en) * 2009-08-24 2012-04-27 Genentech Inc Determining sensitivity of cells to b-raf inhibitor treatment by detecting kras mutation and rtk expression levels
EP2475390A4 (en) * 2009-09-09 2014-01-01 Quintiles Transnat Corp METHODS AND COMPOSITIONS FOR THE TREATMENT OF TYROSINE KINASE RECEPTOR MEDIATION DISEASES OR DISORDERS
CN102115782B (zh) * 2009-12-30 2014-06-18 北京雅康博生物科技有限公司 用于定量检测K-ras突变的试剂盒
JP5808349B2 (ja) 2010-03-01 2015-11-10 カリス ライフ サイエンシズ スウィッツァーランド ホールディングスゲーエムベーハー セラノーシスのためのバイオマーカー
EP2542893A2 (en) * 2010-03-03 2013-01-09 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
US9469876B2 (en) 2010-04-06 2016-10-18 Caris Life Sciences Switzerland Holdings Gmbh Circulating biomarkers for metastatic prostate cancer
CN102869790B (zh) * 2010-04-12 2014-11-26 反应遗传有限公司 Kras引物和探针
WO2011158061A1 (en) 2010-06-15 2011-12-22 Alberto Bardelli Mlk4 gene, a new diagnostic and prognostic marker in cancers
EP3572528A1 (en) 2010-09-24 2019-11-27 The Board of Trustees of the Leland Stanford Junior University Direct capture, amplification and sequencing of target dna using immobilized primers
WO2012049279A1 (en) 2010-10-14 2012-04-19 Universitaet Des Saarlandes MEANS AND METHODS APPLYING SINGLE NUCLEOTIDE PRIMER EXTENSION WITH ION PAIR-, REVERSED-PHASE HPLC (SIRPH) FOR THE DIAGNOSIS OF SNPs
CN103619881B (zh) 2011-04-07 2017-07-28 安姆根有限公司 新的egfr结合蛋白
ITTO20110990A1 (it) 2011-10-28 2013-04-29 Silicon Biosystems Spa Metodo ed apparato per l'analisi ottica di particelle a basse temperature
US9023640B2 (en) * 2011-12-13 2015-05-05 Fundamental Solutions Corporation Device for rapid detection of infectious agents
SG10201708494QA (en) 2012-08-17 2017-11-29 Hoffmann La Roche Combination therapies for melanoma comprising administering cobimetinib and vemurafinib
WO2014052613A2 (en) * 2012-09-26 2014-04-03 Insight Genetics, Inc. Methods and compositions relating to next generation sequencing for genetic testing in alk related cancers
SG11201507739TA (en) * 2013-03-19 2015-10-29 Toppan Printing Co Ltd Method for predicting sensitivity to egfr inhibitor
US10393748B2 (en) 2014-01-07 2019-08-27 Samsung Electronics Co., Ltd. Method for predicting efficacy of c-Met inhibitor
WO2015175705A1 (en) * 2014-05-13 2015-11-19 Board Of Regents, The University Of Texas System Gene mutations and copy number alterations of egfr, kras and met
KR20160037666A (ko) 2014-09-29 2016-04-06 삼성전자주식회사 KRAS 또는 BRAF의 변이를 이용한 c-Met 저해제의 효능 예측
JP2019503767A (ja) 2015-12-22 2019-02-14 アクセス・バスキュラー・インコーポレイテッドＡｃｃｅｓｓ Ｖａｓｃｕｌａｒ， Ｉｎｃ． 高強度生体材
EP3641842A4 (en) 2017-06-21 2021-03-17 Access Vascular, Inc. HIGH STRENGTH POROUS MATERIALS WITH WATER-SOLUBLE POLYMERS
CN107918013A (zh) * 2017-09-25 2018-04-17 浙江天科高新技术发展有限公司 化学发光酶免测定循环肿瘤细胞中K‑Ras蛋白的方法及试剂盒
CN108085390A (zh) * 2017-12-29 2018-05-29 上海桐树生物科技有限公司 肿瘤驱动基因变异的检测剂、检测试剂盒及其应用
AU2021300951A1 (en) 2020-06-30 2023-02-09 Access Vascular, Inc. Articles comprising markings and related methods

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US5151510A (en) 1990-04-20 1992-09-29 Applied Biosystems, Inc. Method of synethesizing sulfurized oligonucleotide analogs
DK0590058T3 (da) 1991-06-14 2004-03-29 Genentech Inc Humaniseret heregulin-antistof
US5470705A (en) 1992-04-03 1995-11-28 Applied Biosystems, Inc. Probe composition containing a binding domain and polymer chain and methods of use
JP2775346B2 (ja) 1992-04-03 1998-07-16 アプライド バイオシステムズ，インコーポレイテッド プローブ構成物および方法
ATE387495T1 (de) 1996-12-03 2008-03-15 Amgen Fremont Inc Vollkommen humane antikörper die egfr binden
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
WO2000055368A2 (en) 1999-03-15 2000-09-21 Pe Corporation (Ny) Probe/mobility modifier complexes for multiplex nucleic acid detection
JP2004507226A (ja) 2000-05-30 2004-03-11 ピーイー　コーポレイション　（エヌワイ） ライゲーションおよび増幅の組み合わせを用いて標的核酸を検出するための方法
US6503914B1 (en) * 2000-10-23 2003-01-07 Board Of Regents, The University Of Texas System Thienopyrimidine-based inhibitors of the Src family
AU2003239505A1 (en) 2002-05-20 2003-12-12 Amgen Fremont Inc. Treatment of renal carcinoma using antibodies against the egfr
KR101289774B1 (ko) * 2004-03-31 2013-08-07 다나-파버 캔서 인스티튜트 인크. 표피성장인자 수용체를 표적으로 하는 치료에 대한 암의반응성을 결정하는 방법
AU2005250484B2 (en) 2004-06-04 2011-08-11 Genentech, Inc. EGFR mutations
WO2006091899A2 (en) * 2005-02-24 2006-08-31 Amgen Inc. Epidermal growth factor receptor mutations
EP1869220A2 (en) * 2005-04-01 2007-12-26 Amgen, Inc. Epidermal growth factor receptor gene copy number
WO2006108627A1 (en) * 2005-04-14 2006-10-19 Merck Patent Gmbh Anti-egfr antibody therapy based on an increased copy number of the egfr gene in tumor tissues
JP2008546421A (ja) * 2005-06-28 2008-12-25 ジェネンテック・インコーポレーテッド Ｅｇｆｒおよびｋｒａｓ変異
US7908091B2 (en) * 2006-03-17 2011-03-15 Prometheus Laboratories Inc. Methods of predicting and monitoring tyrosine kinase inhibitor therapy
MY158649A (en) * 2006-08-10 2016-10-31 Ubukata Ind Co Ltd Thermally responsive switch
EP2118322A2 (en) * 2007-03-13 2009-11-18 Amgen Inc. K-ras and b-raf mutations and anti-egfr antibody therapy
CL2008000717A1 (es) * 2007-03-13 2008-09-22 Amgen Inc Metodo para pronosticar si un paciente sera no respondedor al tratamiento con un agente de union especifica a un polipeptido de egfr que comprende determinar la presencia o ausencia de una mutacion de k-ras en un tumor del paciente.

Also Published As

Publication number Publication date
HK1167005A1 (en) 2012-11-16
SI2412828T1 (sl) 2013-10-30
EP2118322A2 (en) 2009-11-18
JP2013253105A (ja) 2013-12-19
JP2010521154A (ja) 2010-06-24
AU2008226808B2 (en) 2013-04-18
WO2008112274A2 (en) 2008-09-18
HRP20130764T1 (hr) 2013-10-25
EP2412828B1 (en) 2013-06-05
PL2412828T3 (pl) 2013-11-29
TW200904828A (en) 2009-02-01
AR065686A1 (es) 2009-06-24
WO2008112274A3 (en) 2008-12-18
ES2426814T3 (es) 2013-10-25
EP2412828A1 (en) 2012-02-01
CY1114159T1 (el) 2016-08-31
JP2015119726A (ja) 2015-07-02
JP5905422B2 (ja) 2016-04-20
CA2680330A1 (en) 2008-09-18
AU2008226808A1 (en) 2008-09-18
DK2412828T3 (da) 2013-09-02
US20110212456A1 (en) 2011-09-01
PT2412828E (pt) 2013-08-02
PE20090690A1 (es) 2009-06-22
RS52932B (en) 2014-02-28
US20090075267A1 (en) 2009-03-19
CL2008000716A1 (es) 2008-09-22

Similar Documents

Publication Publication Date Title
MX2009009779A (es) Mutaciones de k-ras y b-raf y terapia con anticuerpos anti-egfr.
MX2009009787A (es) Mutaciones de k-ras y terapia con anticuerpos anti-egfr.
JOP20190017B1 (ar) أجسام مضادة ترتبط مع مستقبل cgrp بشري
MX2023007400A (es) Moleculas de union a bcma y metodos de uso de las mismas.
MX2010000537A (es) Anticuerpos monoclonales contra glipicano-3.
SG170080A1 (en) Human monoclonal antibodies to o8e
WO2006089230A3 (en) Human monoclonal antibodies to prostate specific membrane antigen (psma)
EA200800094A1 (ru) Антитела cd19 и их использование
MX2009006277A (es) Anticuerpos humanos que se enlazan a cd70 y usos de los mismos.
WO2007103770A3 (en) Compositions and methods for analyzing renal cancer
UA95068C2 (uk) Антиген-зв'язуюча молекула, яка зв'язує еgfr, вектор, що її кодує, та їх застосування
MX2010005830A (es) Conjugado de anticuerpo monoclonal anti-b7h4 - farmaco y metodos de uso del mismo.
TW200806322A (en) Diagnostics and treatments for tumors
MX2009013410A (es) Biomarcadores para predecir capacidad de respuesta anti-tnf o sin capacidad de respuesta.
UA98983C2 (uk) Антитіло проти гепсидину та його застосування
SG155931A1 (en) Wnt proteins and detection and treatment of cancer
MX2010008570A (es) Anticuerpos alfa5-beta1 y sus usos.
MX2011009220A (es) Anticuerpos completamente humanos especificos para la molecula de adhesion celular 1.
TW200635946A (en) Binding proteins specific for human matriptase
WO2008097466A3 (en) Metastasis specific splice variants of mena and uses thereof in diagnosis, prognosis and treatment of tumors
NZ602840A (en) Immuno-pet imaging of antibodies and immunoconjugates and uses therefor
EP2504363A4 (en) ANTICLUSTERIN ANTIBODIES AND ANTIGEN-BINDING FRAGMENTS AND THEIR USE FOR REDUCING TUMOR VOLUME
WO2008151819A3 (en) Treatment of tumors using specific anti-l1 antibody
BRPI0407680A (pt) métodos para diagnóstico de cáncer e diminuição de metástase por células cancerosas
EA200970884A1 (ru) Способы лечения рака путем введения комбинаций человеческого интерлейкина ил-18

Legal Events

Date Code Title Description
FG Grant or registration